Kyverna Therapeutics, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
5980 Horton Street, Suite 550, Emeryville, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.1M shares
Common Stock, Shares, Outstanding 43.1M shares
Weighted Average Number of Shares Outstanding, Basic 23.8M shares +2478%
Weighted Average Number of Shares Outstanding, Diluted 23.8M shares +2478%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22.5M USD +158%
General and Administrative Expense 6.88M USD +152%
Operating Income (Loss) -29.4M USD -157%
Nonoperating Income (Expense) 2.67M USD +782%
Net Income (Loss) Attributable to Parent -26.7M USD -140%
Earnings Per Share, Basic -1.12 USD/shares +90.7%
Earnings Per Share, Diluted -1.12 USD/shares +90.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 224M USD +464%
Marketable Securities, Current 146M USD
Cash, Cash Equivalents, and Short-term Investments 370M USD
Assets, Current 375M USD
Property, Plant and Equipment, Net 2.71M USD
Operating Lease, Right-of-Use Asset 8.49M USD
Other Assets, Noncurrent 1.17M USD
Assets 390M USD
Accounts Payable, Current 7.45M USD
Liabilities, Current 21.9M USD
Operating Lease, Liability, Noncurrent 6.46M USD
Liabilities 29M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD
Retained Earnings (Accumulated Deficit) -163M USD
Stockholders' Equity Attributable to Parent 361M USD
Liabilities and Equity 390M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5M USD -123%
Net Cash Provided by (Used in) Financing Activities 338M USD
Net Cash Provided by (Used in) Investing Activities -123M USD -1000%
Common Stock, Shares Authorized 490M shares
Common Stock, Shares, Issued 43.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 190M USD +9137%
Interest Paid, Excluding Capitalized Interest, Operating Activities 44K USD 0%
Operating Lease, Liability 9.2M USD
Payments to Acquire Property, Plant, and Equipment 543K USD +1839%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -26.7M USD -140%
Lessee, Operating Lease, Liability, to be Paid 10.5M USD
Property, Plant and Equipment, Gross 5.45M USD
Operating Lease, Liability, Current 2.74M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.34M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 624K USD +10.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 482K USD +22.3%
Share-based Payment Arrangement, Expense 2.28K USD +387%
Interest Expense 44K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares